Shalom Ben-Shimol (Israel)

Soroka University Medical Center Pediatric Infectious Disease Unit
Professor Ben-Shimol graduated from the School of Medicine, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel in 2002, and completed his residency in Pediatrics at the Soroka University Medical Center, Beer-Sheva, Israel in 2008. He has worked as a senior pediatrician at the Department of Pediatrics of the Soroka University Medical Center since 2009 and completed his Fellowship in Infectious Diseases in 2012 at that same hospital. In 2020 he was promoted to the rank of assistant professor in Pediatrics at the Ben-Gurion University of the Negev, Beer-Sheva, Israel. His current research and scientific interests focus on parasitic infections, pneumococcal infections and vaccines. Prof. Ben-Shimol has contributed over 80 peer-reviewed articles, review articles and book chapters both at local and international scientific publications and has presented his work at numerous national and international congresses. He is currently serving on the editorial board of Clinical Infectious Diseases. Prof. Ben-Shimol is a member of the European Society for Paediatric Infectious Diseases, the Israeli Pediatric Society and the Israeli Infectious Diseases Society. He is also a member of the Israeli National Committee on Infectious Diseases and Vaccination. In addition, he has served on several committees at the Faculty of Health Sciences at the Ben-Gurion University of the Negev.

Presenter of 1 Presentation

 Conference Calendar

DYNAMICS OF INVASIVE PNEUMOCOCCAL DISEASE IN ISRAEL IN CHILDREN AND ADULTS IN THE PCV13 ERA; A NATIONWIDE PROSPECTIVE SURVEILLANCE (ID 351)

Session Name
2227 - ORAL PRESENTATIONS 08: VACCINES (NON-RSV) (ID 67)
Lecture Time
10:37 - 10:44
Room
Hall 05
Presenter

Abstract

Background

Following the 13-valent pneumococcal conjugate vaccine (PCV13) implementation in infants worldwide, overall and vaccine-type invasive pneumococcal disease (IPD) rates declined in children, with variable indirect impact on IPD rates in adults.

Methods

A population-based, prospective, nationwide active surveillance of overall 8,614 IPD cases in Israel, during 2004-2019 (for adults, 2009-2019). PCV7/PCV13 were implemented in July 2009/November 2010, respectively, with >90% uptake in children <2 years. The 23-valent pneumococcal polysaccharide vaccine uptake among >65 years was ~75%. Overall, PCV13 serotypes (VT13) and non-VT13 serotypes (NVT) incidence rates ratios were calculated, comparing the pre-PCV (2004-2008 for children; 2009-2011 for adults) and late-PCV13 (2016-2019) periods, for different age groups. For pre-PCV episodes in which serotypes were missing, extrapolation was conducted.

Results

IPD rates declined by 67% in children <5 and 5-17 years. For adults, rates significantly declined only in the 18-44 years (by 53%) (Fig.). VT13 rates significantly declined; range 94% in <5 years to 60% in ≥85 years. NVT rates significantly increased in <5, 50-64 and ≥65 years; VT13 serotypes 3, 14 and 19A, and NVT serotypes 8 and 12F were predominant in 2016-2019. During 2016-2019, VT13, PCV15 additional serotypes (22F, 33F) and PCV20 additional serotypes (8, 10A, 11A, 12F, 15B/C, 22F, 33F) caused 19.2%, 7.4% and 39.2% of IPD.

espid 2021 ben-shimol ipd in all ages fig resized.jpg

Conclusions

Continuous monitoring of circulating serotypes in all age groups is essential for the development of new vaccination strategies.

Hide